PainTEQ, a company specializing in minimally invasive treatments for sacroiliac joint dysfunction, recently announced a significant growth recapitalization led by Signet Healthcare Partners and Windham Capital Partners. These two respected U.S.-based healthcare investors bring nearly 50 years of combined experience in medical technology. The funding round also features a new equity investment from MVolution Partners. This capital injection will support PainTEQ’s plans to expand clinical research, accelerate new product development, and grow its commercial presence across the U.S. market.
Health Technology Insights: Acorn Health Names Mony Iyer CEO
The company’s flagship product, LinQ, is a patented allograft-based implant designed for a drill-less, minimally invasive procedure targeting the sacroiliac joint. LinQ has been used in over 14,000 cases and is supported by multiple peer-reviewed studies, including the SECURE trial, which demonstrated improvements in pain and function along with a strong safety record. CEO Shanth Thiyagalingam, who has more than two decades of experience in interventional medicine from leadership roles at Abbott, Nevro, and Stryker, has led PainTEQ to a position of operational strength and commercial success in this space.
Thiyagalingam described the partnership with Signet and Windham as a key milestone for the company. He emphasized that the strengthened financial foundation and committed ownership group will enable PainTEQ to continue delivering innovative therapies for patients suffering from sacroiliac joint dysfunction. He also expressed gratitude to the founding team and former owners for setting the stage for this next chapter of growth.
Health Technology Insights: Quanterix Accelerator Lab Earns New York Clinical Lab Permit
Dr. Dawood Sayed, Professor and Division Chief of Pain Medicine at the University of Kansas Medical Center as well as Vice Chair and Co-Founder of the American Society of Pain and Neuroscience, said the investment highlights the growing recognition of sacroiliac joint fusion as a vital treatment option. He believes the funding will accelerate research and innovation in interventional spine care, expanding treatment choices and establishing this procedure as a long-term standard of care.
David Kereiakes, Managing Partner at Windham Capital Partners, noted that they were drawn to PainTEQ because of its potential to provide safer and more effective treatments for physicians and patients alike. He praised the company’s innovative approach and strong leadership as critical to meeting the demands of the interventional spine market. Ashley Friedman, Managing Director at Signet Healthcare Partners, shared enthusiasm for the partnership and highlighted PainTEQ’s promising future as a multi-product leader in interventional spine solutions. Raymond James acted as financial advisor to PainTEQ while legal support came from Hill Ward Henderson, Bass Berry & Sims, Sheppard Mullin Richter & Hampton, and Knobbe Martens. Terms of the transaction were not disclosed.
Health Technology Insights: DAWNZERA Approved as First RNA Prophylactic Hereditary Angioedema Treatment
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
